Granted Patent B2

US 8,796,201 · App. 13/289,924 · Granted Aug 5, 2014

Inventors: Lu Shan (Houston, TX); Michael Bethune (Pasadena, CA); Chaitan Khosla (Palo Alto, CA); Jonathan Gass (Collegeville, PA); Gail G. Pyle (Cupertino, CA); Gary M. Gray (Stanford, CA); Indu Isaacs (Andover, MA); Gregg Strohmeier (Newton, MA)

Assignee: The Board of Trustees of the Leland Stanford Junior University

Abstract

Claims (20)

1. A formulation for use in treatment of Celiac Sprue and/or dermatitis herpetiformis, comprising:

an effective dose of two glutenases and a pharmaceutically acceptable excipient wherein said effective dose of two glutenases is formulated in two enzyme doses, one dose containing a prolyl endopeptidase (PEP), and the other dose containing Hordeum vulgare endoprotease.

2. The formulation according to claim 1 , wherein said prolyl endopeptidase is Flavobacterium meningosepticum PEP.

3. The formulation according to claim 1 , wherein said prolyl endopeptidase is Myxococcus xanthus PEP.

4. The formulation according to claim 1 , wherein said prolyl endopeptidase is Sphingomonas capsulate PEP.

5. The formulation according to claim 1 , wherein said prolyl endopeptidase is Lactobacillus helveticus PEP.

6. The formulation according to claim 1 , wherein said prolyl endopeptidase is Penicillium citrinum PEP.

7. The formulation according to claim 1 , wherein said formulation is suitable for oral administration.

8. The formulation according to claim 1 , wherein said formulation comprises an enteric coating.

9. A method of treating Celiac Sprue and/or dermatitis herpetiformis, the method comprising:

administering to a patient an effective dose of a two glutenases;

wherein said effective dose of two glutenases attenuates gluten toxicity in said patient and is administered in two enzyme doses, one dose containing a prolyl endopeptidase (PEP), and the other dose containing Hordeum vulgare endoprotease.

10. The method according to claim 9 , wherein said prolyl endopeptidase is Flavobacterium meningosepticum PEP.

11. The method according to claim 9 , wherein said prolyl endopeptidase is Myxococcus xanthus PEP.

12. The method according to claim 9 , wherein said prolyl endopeptidase is Sphingomonas capsulate PEP.

13. The method according to claim 9 , wherein said prolyl endopeptidase is Lactobacillus helveticus PEP.

14. The method according to claim 9 , wherein said prolyl endopeptidase is Penicillium citrinum PEP.

15. The method according to claim 9 , wherein said glutenase is formulated with a pharmaceutically acceptable excipient.

16. The method according to claim 9 , wherein said effective dose of two glutenases is administered orally.

17. The method according to claim 9 , wherein said effective dose of two glutenases is contained in a formulation that comprises an enteric coating.

Assignments (5)

Continuity (11)